Arformoterol

Arformoterol
Clinical data
Trade names	Brovana
AHFS/Drugs.com	Monograph
MedlinePlus	a602023
License data	US FDA: Arformoterol;
Routes of; administration	Inhalation solution for nebuliser
ATC code	none;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	52–65%
Elimination half-life	26 hours
Identifiers
	IUPAC name N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide;
CAS Number	67346-49-0 ;
PubChem CID	3083544;
IUPHAR/BPS	7479;
DrugBank	DB01274 ;
ChemSpider	2340731 ;
UNII	F91H02EBWT;
ChEBI	CHEBI:408174 ;
ChEMBL	ChEMBL1201137 ;
CompTox Dashboard (EPA)	DTXSID1023077 DTXSID40110071, DTXSID1023077 ;
Chemical and physical data
Formula	C19H24N2O4
Molar mass	344.411 g·mol−1
	InChI InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 ; Key:BPZSYCZIITTYBL-YJYMSZOUSA-N ;
	(what is this?) (verify)

Arformoterol is a long-acting β₂ adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.^[1]

It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.